Also trades as: NYMX (NASDAQ) · $vol 0M
NYMXF OTC
Nymox Pharmaceutical Corporation
1W: -68.0%
1M: +15900.0%
3M: -73.3%
YTD: -31.3%
1Y: -44.4%
3Y: -93.9%
5Y: -98.4%
$0.03
+0.00 (+0.00%)
Weekly Expected Move ±4945.7%
$-3
$-2
$0
$2
$3
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Cash Flow Trends
Operating Cash Flow
-$3M
+35.9% ▲
Capital Expenditures
$0
+100.0% ▲
Free Cash Flow
-$3M
+35.9% ▲
Dividends Paid
$0
+0.0% ▲
Buybacks
$0
+0.0% ▲
Net Change in Cash
$4K
-99.7% ▼
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | -$12M | -$13M | -$7M | -$9M | -$4M |
| Depreciation & Amort. | $9K | $12K | $12K | $11K | $1K |
| Stock-Based Comp. | $2M | $3M | $593K | $3M | $671K |
| Change in Working Capital | -$314K | -$140K | $495K | $821K | $1M |
| Other Non-Cash Items | $2M | $3M | $509K | $598K | $0 |
| Operating Cash Flow | -$10M | -$10M | -$5M | -$4M | -$3M |
| — Investing Activities — | |||||
| Capital Expenditures | -$13K | -$6K | $0 | -$3K | $0 |
| Acquisitions (Net) | $0 | $0 | $0 | $0 | $0 |
| Investment Purchases | $0 | $0 | $0 | $0 | $0 |
| Investment Sales | $0 | $0 | $0 | $0 | $0 |
| Other Investing | $0 | $0 | $0 | $0 | $0 |
| Investing Cash Flow | -$13K | -$6K | $0 | -$3K | $0 |
| — Financing Activities — | |||||
| Net Debt Issuance | -$265K | -$238K | -$229K | $2M | $3M |
| Stock Repurchased | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 |
| Other Financing | $0 | $0 | $0 | -$173K | $0 |
| Financing Cash Flow | $8M | $7M | $6M | $3M | $3M |
| Net Change in Cash | -$2M | -$3M | $573K | $1M | $4K |
| Cash End of Period | $4M | $830K | $1M | -$70K | $74K |
| Free Cash Flow | -$10M | -$10M | -$5M | -$4M | -$3M |